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Viral hepatitis is a term commonly used for several clini-
cally similar yet etiologically and epidemiologically distinct 
diseases. Hepatitis A (formerly called infectious hepatitis) 
and hepatitis B (formerly called serum hepatitis) have been 
recognized as separate entities since the early 1940s and can 
be diagnosed with specific serologic tests. Delta hepatitis 
is an infection dependent on the hepatitis B virus (HBV). It 
may occur as a coinfection with acute HBV infection or as 
superinfection of an HBV carrier.
Epidemic jaundice was described by Hippocrates in the 5th 
century BCE. The first recorded cases of “serum hepatitis,” 
or hepatitis B, are thought to be those that followed the 
administration of smallpox vaccine containing human 
lymph to shipyard workers in Germany in l883. In the early 
and middle parts of the 20th century, serum hepatitis was 
repeatedly observed following the use of contaminated 
needles and syringes. The role of blood as a vehicle for virus 
transmission was further emphasized in 1943, when Beeson 
described jaundice that had occurred in seven recipients of 
blood transfusions. Australia antigen, later called hepatitis B 
surface antigen (HBsAg), was first described in 1965, and the 
Dane particle (complete hepatitis B virion) was identified in 
1970. Identification of serologic markers for HBV infection 
followed, which helped clarify the natural history of the 
disease. Ultimately, HBsAg was prepared in quantity and 
now comprises the immunogen in highly effective vaccines 
for prevention of HBV infection.
Hepatitis B Virus
HBV is a small, double-shelled virus in the family 
Hepadnaviridae. Other Hepadnaviridae include duck hepa-
titis virus, ground squirrel hepatitis virus, and woodchuck 
hepatitis virus. The virus has a small circular DNA genome 
that is partially double-stranded. HBV contains numerous 
antigenic components, including HBsAg, hepatitis B core 
antigen (HBcAg), and hepatitis B e antigen (HBeAg). Humans 
are the only known host for HBV, although some nonhuman 
primates have been infected in laboratory conditions. HBV 
is relatively resilient and, in some instances, has been shown 
to remain infectious on environmental surfaces for more 
than 7 days at room temperature.
An estimated 2 billion persons worldwide have been 
infected with HBV, and more than 350 million persons have 
chronic, lifelong infections. HBV infection is an established 
cause of acute and chronic hepatitis and cirrhosis. It is the 
cause of up to 80% of hepatocellular carcinomas. The World 
Health Organization estimated that more than 600,000 
persons died worldwide in 2002 of hepatitis B-associated 
acute and chronic liver disease.  9
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Several well-defined antigen–antibody systems are associ-
ated with HBV infection. HBsAg, formerly called Australia 
antigen or hepatitis-associated antigen, is an antigenic 
determinant found on the surface of the virus. It also makes 
up subviral 22-nm spherical and tubular particles. HBsAg 
can be identified in serum 30 to 60 days after exposure to 
HBV and persists for variable periods. HBsAg is not infec-
tious. Only the complete virus (Dane particle) is infectious. 
However, when HBsAg is present in the blood, complete 
virus is also present, and the person may transmit the virus. 
During replication, HBV produces HBsAg in excess of that 
needed for production of Dane particles.
HBcAg is the nucleocapsid protein core of HBV. HBcAg is not 
detectable in serum by conventional techniques, but it can 
be detected in liver tissue of persons with acute or chronic 
HBV infection. HBeAg, a soluble protein, is also contained in 
the core of HBV. HBeAg is detected in the serum of persons 
with high virus titers and indicates high infectivity. Antibody 
to HBsAg (anti-HBs) develops during convalescence after 
acute HBV infection or following hepatitis B vaccination. The 
presence of anti-HBs indicates immunity to HBV. (Anti-HBs 
is sometimes referred to as HBsAb, but use of this term is 
discouraged because of potential confusion with HBsAg.) 
Antibody to HBcAg (anti-HBc) indicates infection with HBV at 
an undefined time in the past. IgM class antibody to HBcAg 
(IgM anti-HBc) indicates recent infection with HBV. Antibody 
to HBeAg (anti-HBe) becomes detectable when HBeAg is lost 
and is associated with low infectivity of serum.
Clinical Features
The clinical course of acute hepatitis B is indistinguishable 
from that of other types of acute viral hepatitis. The incuba-
tion period ranges from 45 to 160 days (average,120 days). 
Clinical signs and symptoms occur more often in adults than 
in infants or children, who usually have an asymptomatic 
acute course. However, approximately 50% of adults who 
have acute infections are asymptomatic. 
The preicteric, or prodromal phase from initial symptoms 
to onset of jaundice usually lasts from 3 to l0 days. It 
is nonspecific and is characterized by insidious onset of 
malaise, anorexia, nausea, vomiting, right upper quadrant 
abdominal pain, fever, headache, myalgia, skin rashes, 
arthralgia and arthritis, and dark urine, beginning 1 to 
2 days before the onset of jaundice. The icteric phase is 
variable but usually lasts from l to 3 weeks and is character-
ized by jaundice, light or gray stools, hepatic tenderness 
and hepatomegaly (splenomegaly is less common). During 
convalescence, malaise and fatigue may persist for weeks 
or months, while jaundice, anorexia, and other symptoms 
disappear.117
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Most acute HBV infections in adults result in complete 
recovery with elimination of HBsAg from the blood and the 
production of anti-HBs, creating immunity to future infec-
tion. 
Complications
While most acute HBV infections in adults result in complete 
recovery, fulminant hepatitis occurs in about 1% to 2% of 
acutely infected persons. About 200 to 300 Americans die of 
fulminant disease each year (case-fatality rate 63% to 93%). 
Although the consequences of acute HBV infection can be 
severe, most of the serious complications associated with 
HBV infection are due to chronic infection.
Chronic HBV Infection
Approximately 5% of all acute HBV infections progress to 
chronic infection, with the risk of chronic HBV infection 
decreasing with age. As many as 90% of infants who acquire 
HBV infection from their mothers at birth become chroni-
cally infected. Of children who become infected with HBV 
between 1 year and 5 years of age, 30% to 50% become 
chronically infected. By adulthood, the risk of acquiring 
chronic HBV infection is approximately 5%.
Persons with chronic infection are often asymptomatic and 
may not be aware that they are infected; however, they 
are capable of infecting others and have been referred 
to as carriers. Chronic infection is responsible for most 
HBV-related morbidity and mortality, including chronic 
hepatitis, cirrhosis, liver failure, and hepatocellular 
carcinoma. Approximately 25% of persons with chronic HBV 
infection die prematurely from cirrhosis or liver cancer. 
Chronic active hepatitis develops in more than 25% of 
carriers and often results in cirrhosis. An estimated 3,000 to 
4,000 persons die of hepatitis B-related cirrhosis each year 
in the United States. Persons with chronic HBV infection are 
at 12 to 300 times higher risk of hepatocellular carcinoma 
than noncarriers. An estimated 1,000 to 1,500 persons die 
each year in the United States of hepatitis B-related liver 
cancer.
Laboratory Diagnosis
Diagnosis is based on clinical, laboratory, and epidemiologic 
findings. HBV infection cannot be differentiated on the basis 
of clinical symptoms alone, and definitive diagnosis depends 
on the results of serologic testing. Serologic markers of HBV 
infection vary depending on whether the infection is acute 
or chronic.
HBsAg is the most commonly used test for diagnosing 
acute HBV infections or detecting carriers. HBsAg can be 
detected as early as 1 or 2 weeks and as late as 11 or 12   9
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weeks after exposure to HBV when sensitive assays are used. 
The presence of HBsAg indicates that a person is infectious, 
regardless of whether the infection is acute or chronic.
Anti-HBc (core antibody) develops in all HBV infections, 
appears shortly after HBsAg in acute disease, and indicates 
HBV infection at some undefined time in the past. Anti-HBc 
only occurs after HBV infection and does not develop in 
persons whose immunity to HBV is from vaccine. Anti-HBc 
generally persists for life and is not a serologic marker for 
acute infection.
IgM anti-HBc appears in persons with acute disease about 
the time of illness onset and indicates recent infection with 
HBV. IgM anti-HBc is generally detectable 4 to 6 months 
after onset of illness and is the best serologic marker 
of acute HBV infection. A negative test for IgM-anti-HBc 
together with a positive test for HBsAg in a single blood 
sample identifies a chronic HBV infection.119
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HBeAg is a useful marker associated strongly with the 
number of infective HBV particles in the serum and a higher 
risk of infectivity.
Anti-HBs (surface antibody) is a protective, neutralizing 
antibody. The presence of anti-HBs following acute HBV 
infection generally indicates recovery and immunity against 
reinfection. Anti-HBs can also be acquired as an immune 
response to hepatitis B vaccine or passively transferred 
by administration of hepatitis B immune globulin (HBIG). 
When using radioimmunoassay (RIA), a minimum of 10 
sample ratio units should be used to designate immunity. 
With enzyme immunoassay (EIA), the manufacturer’s 
recommended positive should be considered an appropriate 
measure of immunity. The level of anti-HBs may also be 
expressed in milli-international units/mL (mIU/mL). Ten 
mIU/mL is considered to indicate a protective level of 
immunity.
Medical Management
There is no specific therapy for acute HBV infection. 
Treatment is supportive. Interferon is the most effective 
treatment for chronic HBV infection and is successful in 25% 
to 50% of cases.
Persons with acute or chronic HBV infections should prevent 
their blood and other potentially infective body fluids from 
contacting other persons. They should not donate blood or 
share toothbrushes or razors with household members.
In the hospital setting, patients with HBV infection should 
be managed with standard precautions.
Epidemiology
Reservoir
Although other primates have been infected in laboratory 
conditions, HBV infection affects only humans. No animal or 
insect hosts or vectors are known to exist.
Transmission
The virus is transmitted by parenteral or mucosal exposure 
to HBsAg-positive body fluids from persons who have acute 
or chronic HBV infection. The highest concentrations of 
virus are in blood and serous fluids; lower titers are found 
in other fluids, such as saliva and semen. Saliva can be a 
vehicle of transmission through bites; however, other types 
of exposure to saliva, including kissing, are unlikely modes 
of transmission. There appears to be no transmission of HBV 
via tears, sweat, urine, stool, or droplet nuclei.  9
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In the United States, the most important route of transmis-
sion is by sexual contact, either heterosexual or homosexual, 
with an infected person. Fecal-oral transmission does not 
appear to occur. However, transmission occurs among men 
who have sex with men, possibly via contamination from 
asymptomatic rectal mucosal lesions.
Direct percutaneous inoculation of HBV by needles during 
injection-drug use is an important mode of transmission. 
Transmission of HBV may also occur by other percutaneous 
exposure, including tattooing, ear piercing, and acupunc-
ture, as well as needlesticks or other injuries from sharp 
instruments sustained by medical personnel. These expo-
sures account for only a small proportion of reported cases 
in the United States. Breaks in the skin without overt needle 
puncture, such as fresh cutaneous scratches, abrasions, 
burns, or other lesions, may also serve as routes for entry.
Contamination of mucosal surfaces with infective serum or 
plasma may occur during mouth pipetting, eye splashes, 
or other direct contact with mucous membranes of the 
eyes or mouth, such as hand-to-mouth or hand-to-eye 
contact when hands are contaminated with infective blood 
or serum. Transfer of infective material to skin lesions or 
mucous membranes via inanimate environmental surfaces 
may occur by touching surfaces of various types of hospital 
equipment. Contamination of mucosal surfaces with infec-
tive secretions other than serum or plasma could occur with 
contact involving semen.
Perinatal transmission from mother to infant at birth is 
very efficient. If the mother is positive for both HBsAg and 
HBeAg, 70%–90% of infants will become infected in the 
absence of postexposure prophylaxis. The risk of perinatal 
transmission is about 10% if the mother is positive only 
for HBsAg. As many as 90% of these infected infants will 
become chronically infected with HBV. 
The frequency of infection and patterns of transmission 
vary in different parts of the world. Approximately 45% of 
the global population live in areas with a high prevalence 
of chronic HBV infection (8% or more of the population is 
HBsAg positive), 43% in areas with a moderate prevalence 
(2% to 7% of the population is HBsAg positive), and 12% in 
areas with a low prevalence (less than 2% of the population 
is HBsAg positive).
In China, Southeast Asia, most of Africa, most Pacific Islands, 
parts of the Middle East, and the Amazon Basin, 8% to 
l5% of the population carry the virus. The lifetime risk of 
HBV infection is greater than 60%, and most infections are 
acquired at birth or during early childhood, when the risk 
of developing chronic infections is greatest. In these areas, 
because most infections are asymptomatic, very little acute 121
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disease related to HBV occurs, but rates of chronic liver 
disease and liver cancer among adults are very high. In the 
United States, Western Europe, and Australia, HBV infection 
is a disease of low endemicity. Infection occurs primarily 
during adulthood, and only 0.1% to 0.5% of the population 
are chronic carriers. Lifetime risk of HBV infection is less 
than 20% in low prevalence areas.
Communicability
Persons with either acute or chronic HBV infection should 
be considered infectious any time that HBsAg is present 
in the blood. When symptoms are present in persons with 
acute HBV infection, HBsAg can be found in blood and 
body fluids for 1–2 months before and after the onset of 
symptoms.
Secular Trends in the United States
Hepatitis has been reportable in the United States for 
many years. Hepatitis B became reportable as a distinct 
entity during the 1970s, after serologic tests to differentiate 
different types of hepatitis became widely available.
The incidence of reported hepatitis B peaked in the 
mid-1980s, with about 26,000 cases reported each year. 
Reported cases have declined since that time, and fell below 
10,000 cases for the first time in 1996. The decline in cases 
during the 1980s and early 1990s is generally attributed to 
reduction of transmission among men who have sex with men 
and injection-drug users as a result of HIV prevention efforts.
During 1990–2004, incidence of acute hepatitis B in the 
United States declined 75%. The greatest decline (94%) 
occurred among children and adolescents, coincident with 
an increase in hepatitis B vaccine coverage. A total of 3,405 
cases of hepatitis B were reported in 2009.
Reported cases of HBV infection represent only a fraction 
of cases that actually occur. In 2001, a total of 7,844 cases 
of acute hepatitis B were reported to CDC. Based on these 
reports, CDC estimates that 22,000 acute cases of hepatitis 
B resulted from an estimated 78,000 new infections. An 
estimated 700,000 to 1.4 million persons in the United 
States are chronically infected with HBV, and an additional 
5,000–8,000 persons become chronically infected each year.
Before routine childhood hepatitis B vaccination was recom-
mended, more than 80% of acute HBV infections occurred 
among adults. Adolescents accounted for approximately 
8% of infections, and children and infants infected through 
perinatal transmission accounted for approximately 4% 
each. Perinatal transmission accounted for a dispropor-
tionate 24% of chronic infections.  9
Hepatitis B
122
In the United States in 2005, the highest incidence of 
acute hepatitis B was among adults aged 25–45 years. 
Approximately 79% of persons with newly acquired hepatitis 
B infection are known to engage in high-risk sexual activity 
or injection-drug use. Other known exposures (i.e., occupa-
tional, household, travel, and healthcare-related) together 
account for 5% of new infections. Approximately 16% of 
persons deny a specific risk factor for infection.
Although HBV infection is uncommon among adults in the 
general population (the lifetime risk of infection is less 
than 20%), it is highly prevalent in certain groups. Risk for 
infection varies with occupation, lifestyle, or environment 
(see table). Generally, the highest risk for HBV infection is 
associated with lifestyles, occupations, or environments in 
which contact with blood from infected persons is frequent. 
In addition, the prevalence of HBV markers for acute or 
chronic infection increases with increasing number of years 
of high-risk behavior. For instance, an estimated 40% of 
injection-drug users become infected with HBV after 1 year 
of drug use, while more than 80% are infected after 10 years.123
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Hepatitis B Prevention Strategies
Hepatitis B vaccines have been available in the United States 
since 1981. However, the impact of vaccine on HBV disease 
has been less than optimal.
The apparent lack of impact from the vaccine can be attrib-
uted to several factors. From 1981 until 1991, vaccination 
was targeted to persons in groups at high risk of acquiring 
HBV infection. A large proportion of persons with HBV 
infection (25% to 30%) deny having any risk factors for the 
disease. These persons would not be identified by a targeted 
risk factor screening approach.
The three major risk groups (heterosexuals with contact with 
infected persons or multiple partners, injection-drug users, 
and men who have sex with men) are not reached effectively 
by targeted programs. Deterrents to immunization of these 
groups include lack of awareness of the risk of disease and 
its consequences, lack of effective public or private sector 
programs, and vaccine cost. Difficulty in gaining access to 
these populations is also a problem. Further, success in 
providing vaccine to persons in high-risk groups has been 
limited because of rapid acquisition of infection after begin-
ning high-risk behaviors, low initial vaccine acceptance, and 
low rates of completion of vaccinations.
A comprehensive strategy to eliminate hepatitis B virus 
transmission was recommended in 1991; it includes 
prenatal testing of pregnant women for HBsAg to identify 
newborns who require immunoprophylaxis for prevention 
of perinatal infection and to identify household contacts 
who should be vaccinated, routine vaccination of infants, 
vaccination of adolescents, and vaccination of adults at high 
risk for infection. Recommendations to further enhance 
vaccination of adults at increased risk of HBV infection were 
published in 2006.
Hepatitis B Vaccine
Characteristics
A plasma-derived vaccine was licensed in the United States 
in 1981. It was produced from 22-nm HBsAg particles 
purified from the plasma of chronically infected humans. 
The vaccine was safe and effective but was not well 
accepted, possibly because of unsubstantiated fears of trans-
mission of live HBV and other bloodborne pathogens (e.g., 
human immunodeficiency virus). This vaccine was removed 
from the U.S. market in 1992.
Recombinant hepatitis B vaccine was licensed in the United 
States in July 1986. A second, similar vaccine was licensed in 
August 1989.  9
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Recombinant vaccine is produced by inserting a plasmid 
containing the gene for HBsAg into common baker’s yeast 
(Saccharomyces cerevisiae). Yeast cells then produce HBsAg, 
which is harvested and purified. The recombinant vaccine 
contains more than 95% HBsAg protein (5 to 40 mcg/mL); 
yeast-derived proteins may constitute up to 5% of the final 
product, but no yeast DNA is detectable in the vaccine. 
HBV infection cannot result from use of the recombinant 
vaccine, since no potentially infectious viral DNA or 
complete viral particles are produced in the recombi-
nant system. Vaccine HBsAg is adsorbed to aluminum 
hydroxide.
Hepatitis B vaccine is produced by two manufacturers 
in the United States, Merck (Recombivax HB) and 
GlaxoSmithKline Pharmaceuticals (Engerix-B). Both 
vaccines are available in both pediatric and adult formu-
lations. Although the antigen content of the vaccines 
differs, vaccines made by different manufacturers are 
interchangeable, except for the two-dose schedule for 
adolescents aged 11 through 15 years. Only Merck vaccine 
is approved for this schedule. Providers must always follow 
the manufacturer’s dosage recommendations.
Both the pediatric and adult formulations of Recombivax 
HB are approved for use in any age group. For example, 
the adult formulation of Recombivax HB may be used 
in children (0.5 mL) and adolescents (0.5 mL). However, 
pediatric Engerix-B is approved for use only in children 
and adolescents younger than 20 years of age. The adult 
formulation of Engerix-B is not approved for use in infants 
and children but may be used in both adolescents (11 
through 19 years of age) and adults.
Engerix-B contains aluminum hydroxide as an adjuvant. It 
does not contain thimerosal as a preservative but contains 
a trace of thimerosal as residual from the manufacturing 
process. The vaccine is supplied in single-dose vials and 
syringes. Recombivax HB contains aluminum hydroxyphos-
phate sulfate as an adjuvant. None of the formulations of 
Recombivax HB contain thimerosal or any other preserva-
tive. The vaccine is supplied in single-dose vials.
Immunogenicity and Vaccine Efficacy
After three intramuscular doses of hepatitis B vaccine, 
more than 90% of healthy adults and more than 95% of 
infants, children, and adolescents (from birth to 19 years of 
age) develop adequate antibody responses. However, there 
is an age-specific decline in immunogenicity. After age 40 
years, approximately 90% of recipients respond to a three-
dose series, and by 60 years, only 75% of vaccinees develop 125
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protective antibody titers. The proportion of recipients who 
respond to each dose varies by age (see table).
The vaccine is 80% to 100% effective in preventing infection 
or clinical hepatitis in those who receive the complete 
course of vaccine. Larger vaccine doses (2 to 4 times the 
normal adult dose) or an increased number of doses are 
required to induce protective antibody in a high proportion 
of hemodialysis patients and may also be necessary in other 
immunocompromised persons. 
The recommended dosage of vaccine differs depending 
on the age of the recipient and type of vaccine (see table). 
Hemodialysis patients should receive a 40-mcg dose in a 
series of three or four doses. Recombivax HB has a special 
dialysis patient formulation that contains 40 mcg/mL.  9
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The deltoid muscle is the recommended site for hepatitis 
B vaccination in adults and children, while the antero-
lateral thigh is recommended for infants and neonates. 
Immunogenicity of vaccine in adults is lower when injec-
tions are given in the gluteus. Hepatitis B vaccine should 
be administered to newborns using a needle of at least 5/8 
inch length and to older children and adults of at least 1 
inch length. Hepatitis B vaccine administered by any route 
or site other than intramuscularly in the anterolateral 
thigh or deltoid muscle should not be counted as valid and 
should be repeated unless serologic testing indicates that an 
adequate response has been achieved.
Available data show that vaccine-induced antibody levels 
decline with time. However, immune memory remains 
intact for more than 20 years following immunization, and 
both adults and children with declining antibody levels are 
still protected against significant HBV infection (i.e., clinical 
disease, HBsAg antigenemia, or significant elevation of 
liver enzymes). Exposure to HBV results in an anamnestic 
anti-HBs response that prevents clinically significant HBV 
infection. Chronic HBV infection has only rarely been docu-
mented among vaccine responders.
For adults and children with normal immune status, booster 
doses of vaccine are not recommended. Routine serologic 
testing to assess immune status of vaccinees is not recom-
mended. The need for booster doses after longer intervals 
will continue to be assessed as additional information 
becomes available.
For hemodialysis patients, the need for booster doses should 
be assessed by annual testing of vaccinees for antibody 
levels, and booster doses should be provided when antibody 
levels decline below 10 mIU/mL.
Vaccination Schedule and Use
Infants and Children
Hepatitis B vaccination is recommended for all infants soon 
after birth and before hospital discharge. Infants and children 
younger than 11 years of age should receive 0.5 mL (5 mcg) of 
pediatric or adult formulation Recombivax HB (Merck) or 0.5 
mL (10 mcg) of pediatric Engerix-B (GlaxoSmithKline). Primary 
vaccination consists of three intramuscular doses of vaccine. 
The usual schedule is 0, 1 to 2, and 6 to 18 months. Infants 
whose mothers are HBsAg positive or whose HBsAg status is 
unknown should receive the last (third or fourth) dose by 6 
months of age (12 to 15 months if Comvax is used).
Because the highest titers of anti-HBs are achieved when 
the last two doses of vaccine are spaced at least 4 months 
apart, schedules that achieve this spacing are preferable. 127
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However, schedules with 2-month intervals between doses, 
which conform to schedules for other childhood vaccines, 
have been shown to produce good antibody responses and 
may be appropriate in populations in which it is difficult to 
ensure that infants will be brought back for all their vaccina-
tions. However, the third dose must be administered at least 
8 weeks after the second dose, and should follow the first 
dose by at least 16 weeks. For infants, the third dose should 
not be given earlier than 24 weeks of age. It is not necessary 
to add doses or restart the series if the interval between 
doses is longer than recommended.
Preterm infants born to HBsAg-positive women and women 
with unknown HBsAg status must receive immunopro-
phylaxis with hepatitis B vaccine and hepatitis B immune 
globulin (HBIG) within 12 hours of birth. See the section on 
Postexposure Prophylaxis for additional information. Preterm 
infants with low birthweight (i.e., less than 2,000 grams) have 
a decreased response to hepatitis B vaccine administered 
before 1 month of age. However, by chronologic age 1 month, 
preterm infants, regardless of initial birthweight or gesta-
tional age, are as likely to respond as adequately as full-term 
infants. Preterm infants of low birthweight whose mothers 
are HBsAg negative can receive the first dose of the hepatitis 
B vaccine series at chronologic age 1 month. Preterm infants 
discharged from the hospital before chronologic age 1 month 
can also be administered hepatitis B vaccine at discharge 
if they are medically stable and have gained weight consis-
tently. The full recommended dose should be used. Divided 
or reduced doses are not recommended.
Comvax
Hepatitis B vaccine is available in combination with 
Haemophilus influenzae type b (Hib) vaccine as Comvax 
(Merck). Each dose of Comvax contains 7.5 mcg of PRP-OMP 
Hib vaccine (PedvaxHIB), and 5 mcg of hepatitis B surface 
antigen. The dose of hepatitis B surface antigen is the same 
as that contained in Merck’s pediatric formulation. The 
immunogenicity of the combination vaccine is equivalent to 
that of the individual antigens administered at separate sites.
Comvax is licensed for use at 2, 4, and 12 through 15 months 
of age. It may be used whenever either antigen is indicated 
and the other antigen is not contraindicated. However, the 
vaccine must not be administered to infants younger than 6 
weeks of age because of potential suppression of the immune 
response to the Hib component (see Chapter 7, Haemophilus 
influenzae type b, for more details). Comvax must not be used 
for doses at birth or 1 month of age for a child on a 0, 1, 6 
month hepatitis B vaccine schedule. Although it is not labeled 
for this indication by FDA, ACIP recommends that Comvax 
may be used in infants whose mothers are HBsAg positive or 
whose HBsAg status is unknown.  9
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Pediarix
In 2002, the Food and Drug Administration approved 
Pediarix (GlaxoSmithKline), the first pentavalent (5-compo-
nent) combination vaccine licensed in the United States. 
Pediarix contains DTaP (Infanrix), hepatitis B (Engerix-B), 
and inactivated polio vaccines. In prelicensure studies, 
the proportion of children who developed a protective 
level of antibody, and the titer of antibody, were at least 
as high among children receiving the vaccine antigens 
given together as Pediarix as among children who received 
separate vaccines. 
The minimum age for the first dose of Pediarix is 6 weeks, 
so it cannot be used for the birth dose of the hepatitis B 
series. Pediarix is approved for the first three doses of the 
DTaP and IPV series, which are usually given at about 2, 4, 
and 6 months of age; it is not approved for fourth or fifth 
(booster) doses of the DTaP or IPV series. However, Pediarix 
is approved for use through 6 years of age. A child who 
is behind schedule can still receive Pediarix as long as it 
is given for doses 1, 2, or 3 of the series, and the child is 
younger than 7 years of age.
A dose of Pediarix inadvertently administered as the fourth 
or fifth dose of the DTaP or IPV series does not need to be 
repeated.
Pediarix may be used interchangeably with other pertussis-
containing vaccines if necessary (although ACIP prefers the 
use of the same brand of DTaP for all doses of the series, 
if possible). It can be given at 2, 4, and 6 months to infants 
who received a birth dose of hepatitis B vaccine (total of 
4 doses of hepatitis B vaccine). Although not labeled for 
this indication by FDA, Pediarix may be used in infants 
whose mothers are HBsAg positive or whose HBsAg status is 
unknown.
Adolescents
Routine hepatitis B vaccination is recommended for 
all children and adolescents through age 18 years. All 
children not previously vaccinated with hepatitis B vaccine 
should be vaccinated at 11 or 12 years of age with the 
age-appropriate dose of vaccine. When adolescent vaccina-
tion programs are being considered, local data should be 
considered to determine the ideal age group to vaccinate 
(i.e., preadolescents, young adolescents) to achieve the 
highest vaccination rates. The vaccination schedule should 
be flexible and should take into account the feasibility 
of delivering three doses of vaccine to this age group. 
Unvaccinated older adolescents should be vaccinated 
whenever possible. Those in groups at risk for HBV infec-
tion (e.g., Asian and Pacific Islanders, sexually active) 
should be identified and vaccinated in settings serving 129
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this age group (i.e., schools, sexually transmitted disease 
clinics, detention facilities, drug treatment centers).
Persons younger than 20 years of age should receive 0.5 
mL (5 mcg) of pediatric or adult formulation Recombivax 
HB (Merck) or 0.5 mL (10 mcg) of pediatric formulation 
Engerix-B (GlaxoSmithKline). The adult formulation of 
Engerix-B may be used in adolescents, but the approved 
dose is 1 mL (20 mcg).
The usual schedule for adolescents is two doses separated 
by no less than 4 weeks, and a third dose 4 to 6 months 
after the second dose. If an accelerated schedule is needed, 
the minimum interval between the first two doses is 4 
weeks, and the minimum interval between the second and 
third doses is 8 weeks. However, the first and third doses 
should be separated by no less than 16 weeks. Doses given 
at less than these minimum intervals should not be counted 
as part of the vaccination series.
In 1999, the Food and Drug Administration approved an 
alternative hepatitis B vaccination schedule for adolescents 
11 through 15 years of age. This alternative schedule is for 
two 1.0-mL (10 mcg) doses of Recombivax HB separated 
by 4 to 6 months. Seroconversion rates and postvac-
cination anti-HBs antibody titers were similar using this 
schedule or the standard schedule of three 5-mcg doses 
of RecombivaxHB. This alternative schedule is approved 
only for adolescents 11 through 15 years of age, and for 
Merck’s hepatitis B vaccine. The 2-dose schedule should be 
completed by age 16 years.
Adults (20 Years of Age and Older)
Routine preexposure vaccination should be considered for 
groups of adults who are at increased risk of HBV infection. 
Adults 20 years of age and older should receive 1 mL (10 
mcg) of pediatric or adult formulation Recombivax HB 
(Merck) or 1 mL (20 mcg) of adult formulation Engerix-B 
(GlaxoSmithKline). The pediatric formulation of Engerix-B is 
not approved for use in adults.
The usual schedule for adults is two doses separated by 
no less than 4 weeks, and a third dose 4 to 6 months after 
the second dose. If an accelerated schedule is needed, the 
minimum interval between the first two doses is 4 weeks, 
and the minimum interval between the second and third 
doses is 8 weeks. However, the first and third doses should 
be separated by no less than 16 weeks. Doses given at less 
than these minimum intervals should not be counted as 
part of the vaccination series. It is not necessary to restart 
the series or add doses because of an extended interval 
between doses.  9
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Hepatitis B vaccination is recommended for all unvaccinated 
adults at risk for HBV infection and for all adults requesting 
protection from HBV infection. Acknowledgment of a specific 
risk factor should not be a requirement for vaccination.
Persons at risk for infection by sexual exposure include sex 
partners of HBsAg-positive persons, sexually active persons 
who are not in a long-term, mutually monogamous relation-
ship (e.g., persons with more than one sex partner during 
the previous 6 months), persons seeking evaluation or treat-
ment for a sexually transmitted disease, and men who have 
sex with men.
Persons at risk for infection by percutaneous or mucosal 
exposure to blood include current or recent injection-drug 
users (IDU), household contacts of HBsAg-positive persons, 
residents and staff of facilities for developmentally disabled 
persons, healthcare and public safety workers with risk for 
exposure to blood or blood-contaminated body fluids and 
persons with end-stage renal disease, including predialysis, 
hemodialysis, peritoneal dialysis, and home dialysis 
patients. 
Adults with diabetes mellitus (type 1 or type 2) are at 
increased risk of HBV infection, probably because of 
breaches in infection control during assisted blood glucose 
monitoring (e.g., reuse of single patient finger stick 
devices). In October 2011, ACIP recommended that all 
previously unvaccinated adults 19 through 59 years of age 
with diabetes mellitus (type 1 and type 2) be vaccinated 
against hepatitis B as soon as possible after a diagnosis of 
diabetes is made. ACIP also recommended that unvaccinated 
adults aged 60 years of age or older with diabetes may be 
vaccinated at the discretion of the treating clinician after 
assessing their risk and the likelihood of an adequate 
immune response to vaccination.
Others groups at risk include international travelers to 
regions with high or intermediate levels (HBsAg prevalence 
of 2% or higher) of endemic HBV infection and persons with 
HIV infection. 
In settings in which a high proportion of adults have risks 
for HBV infection (e.g., sexually transmitted disease/human 
immunodeficiency virus testing and treatment facilities, drug-
abuse treatment and prevention settings, healthcare settings 
targeting services to IDUs, healthcare settings targeting 
services to MSM, and correctional facilities), ACIP recom-
mends universal hepatitis B vaccination for all unvaccinated 
adults. In other primary care and specialty medical settings in 
which adults at risk for HBV infection receive care, healthcare 
providers should inform all patients about the health benefits 
of vaccination, including risks for HBV infection and persons 
for whom vaccination is recommended, and vaccinate adults 131
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who report risks for HBV infection and any adults requesting 
protection from HBV infection. 
Twinrix 
In 2001, the Food and Drug Administration approved a 
combination hepatitis A and hepatitis B vaccine (Twinrix, 
GlaxoSmithKline). Each dose of Twinrix contains 720 ELISA 
units of hepatitis A vaccine (equivalent to a pediatric dose 
of Havrix), and 20 mcg of hepatitis B surface antigen protein 
(equivalent to an adult dose of Engerix-B). The vaccine is 
administered in a three-dose series at 0, 1, and 6 months. 
Appropriate spacing of the doses must be maintained to 
assure long-term protection from both vaccines. The first 
and third doses of Twinrix should be separated by at least 6 
months. The first and second doses should be separated by 
at least 4 weeks, and the second and third doses should be 
separated by at least 5 months. In 2007, the FDA approved 
an alternative Twinrix schedule of doses at 0, 7, and 21–31 
days and a booster dose 12 months after the first dose. 
It is not necessary to restart the series or add doses if the 
interval between doses is longer than the recommended 
interval.
Twinrix is approved for persons aged 18 years and older, and 
can be used in persons in this age group with indications 
for both hepatitis A and hepatitis B vaccines. Because the 
hepatitis B component of Twinrix is equivalent to a standard 
dose of hepatitis B vaccine, the schedule is the same 
whether Twinrix or single-antigen hepatitis B vaccine is used. 
Single-antigen hepatitis A vaccine can be used to complete a 
series begun with Twinrix and vice versa. See the Hepatitis A 
chapter for details.
Serologic Testing of Vaccine Recipients
Prevaccination Serologic Testing
The decision to screen potential vaccine recipients for 
prior infection depends on the cost of vaccination, the cost 
of testing for susceptibility, and the expected prevalence 
of immune persons in the population being screened. 
Prevaccination testing is recommended for all foreign-born 
persons (including immigrants, refugees, asylum seekers, 
and internationally adopted children) born in Africa, Asia, 
the Pacific Islands, and other regions with endemicity of 
HBV infection; for household, sex, and needle-sharing 
contacts of HBsAg-positive persons; men who have sex with 
men, injection drug users, and for certain persons receiving 
cytotoxic or immunosuppressive therapy. Screening is 
usually cost-effective, and should be considered for 
groups with a high risk of HBV infection (prevalence of 
HBV markers 20% or higher), such as men who have sex 
with men, injection-drug users, and incarcerated persons.   9
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Screening is usually not cost-effective for groups with a 
low expected prevalence of HBV serologic markers, such as 
health professionals in their training years.
Serologic testing is not recommended before routine vacci-
nation of infants and children.
Postvaccination Serologic Testing
Testing for immunity following vaccination is not recom-
mended routinely but should be considered for persons 
whose subsequent management depends on knowledge of 
their immune status, such as chronic hemodialysis patients, 
other immunocompromised persons and persons with HIV 
infection. Testing is also recommended for sex partners of 
HBsAg-positive persons. When necessary, postvaccination 
testing should be performed 1 to 2 months after completion 
of the vaccine series.
Infants born to HBsAg-positive women should be tested for 
HBsAg and antibody to HBsAg (anti-HBs) after completion 
of at least 3 doses of the hepatitis B vaccine series, at age 
9 through 18 months (generally at the next well-child visit).
If HBsAg is not present and anti-HBs antibody is present, 
children can be considered to be protected.
Healthcare personnel who have contact with patients 
or blood and are at ongoing risk for injuries with sharp 
instruments or needlesticks should be routinely tested for 
antibody after 1 to 2 months after completion of the 3-dose 
series. However, a catch-up program of serologic testing for 
healthcare personnel is not recommended. These persons 
should be tested as necessary if they have a significant 
exposure to HBV (see postexposure prophylaxis section).
Routine postvaccination testing is not recommended for 
persons at low risk of exposure, such as public safety 
workers and healthcare personnel without direct patient 
contact.
Vaccine Nonresponse
Several factors have been associated with nonresponse to 
hepatitis B vaccine. These include vaccine factors (e.g., dose, 
schedule, injection site) and host factors. Older age (40 years 
and older), male sex, obesity, smoking, and chronic illness 
have been independently associated with nonresponse to 
hepatitis B vaccine. Further vaccination of persons who fail 
to respond to a primary vaccination series administered in 
the deltoid muscle produces adequate response in 15% to 
25% of vaccinees after one additional dose and in 30% to 
50% after three additional doses.
Persons who do not respond to the first series of hepatitis B 
vaccine should complete a second three-dose vaccine series. 133
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The second vaccine series should be given on the usual 0, 
1, 6-month schedule. A 0, 1, 4-month accelerated schedule 
may also be used. Revaccinated healthcare personnel and 
others for whom postvaccination serologic testing is recom-
mended should be retested 1 to 2 months after completion 
of the second vaccine series. 
Fewer than 5% of persons receiving six doses of hepatitis 
B vaccine administered by the appropriate schedule in the 
deltoid muscle fail to develop detectable anti-HBs antibody. 
Some persons who are anti-HBs negative following six doses 
may have a low level of antibody that is not detected by 
routine serologic testing (“hyporesponder”). However, one 
reason for persistent nonresponse to hepatitis B vaccine is 
that the person is chronically infected with HBV. Persons 
who fail to develop detectable anti-HBs after six doses 
should be tested for HBsAg. Persons who are found to be 
HBsAg positive should be counseled accordingly. Persons 
who fail to respond to two appropriately administered 
three-dose series, and who are HBsAg negative should be 
considered susceptible to HBV infection and should be 
counseled regarding precautions to prevent HBV infection 
and the need to obtain HBIG prophylaxis for any known or 
probable parenteral exposure to HBsAg-positive blood (see 
the postexposure prophylaxis table in this chapter). 
It is difficult to interpret the meaning of a negative anti-HBs 
serologic response in a person who received hepatitis B 
in the past and was not tested after vaccination. Without 
postvaccination testing 1 to 2 months after completion of 
the series, it is not possible to determine if persons testing 
negative years after vaccination represent true vaccine 
failure (i.e., no initial response), or have anti-HBs antibody 
that has waned to below a level detectable by the test. The 
latter is the most likely explanation, because up to 60% of 
vaccinated people lose detectable antibody (but not protec-
tion) 9 to 15 years after vaccination.
One management option is to assume true vaccine failure 
and administer a second series to these persons. Serologic 
testing for anti-HBs antibody should be repeated 1 to 2 
months after the sixth dose.
A second, probably less expensive option is to administer 
a single dose of hepatitis B vaccine and test for hepatitis B 
surface antibody in 4 to 6 weeks. If the person is anti-HBs 
antibody positive, this most likely indicates a booster 
response in a previous responder, and no further vaccina-
tion (or serologic testing) is needed. If the person is anti-HBs 
antibody negative after this “booster” dose, a second series 
should be completed (i.e., two more doses). If the person is 
still seronegative after six total doses, he or she should be 
managed as a nonresponder (see Postexposure Management, 
on the next page).  9
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Postexposure Management
Hepatitis B vaccine is recommended as part of the therapy 
used to prevent hepatitis B infection following exposure to 
HBV. Depending on the exposure circumstance, the hepatitis 
B vaccine series may be started at the same time as treat-
ment with hepatitis B immune globulin (HBIG).
HBIG is prepared by cold ethanol fraction of plasma from 
selected donors with high anti-HBs titers; it contains an 
anti-HBs titer of at least 1:100,000, by RIA. It is used for 
passive immunization for accidental (percutaneous, mucous 
membrane) exposure, sexual exposure to an HBsAg-positive 
person, perinatal exposure of an infant, or household 
exposure of an infant younger than 12 months old to a 
primary caregiver with acute hepatitis B. Most candidates 
for HBIG are, by definition, in a high-risk category and 
should therefore be considered for vaccine as well.
Immune globulin (IG) is prepared by cold ethanol fraction-
ation of pooled plasma and contains low titers of anti-HBs. 
Because titers are relatively low, IG has no valid current 
use for HBV disease unless hepatitis B immune globulin is 
unavailable.
Infants born to women who are HBsAg-positive (i.e., acutely 
or chronically infected with HBV) are at extremely high risk 
of HBV transmission and chronic HBV infection. Hepatitis 
B vaccination and one dose of HBIG administered within 
24 hours after birth are 85%–95% effective in preventing 
both acute HBV infection and chronic infection. Hepatitis 
B vaccine administered alone beginning within 24 hours 
after birth is 70%–95% effective in preventing perinatal HBV 
infection.
HBIG (0.5 mL) should be given intramuscularly (IM), prefer-
ably within 12 hours of birth. Hepatitis B vaccine should be 
given IM in three doses. The first dose should be given at the 
same time as HBIG, but at a different site. If vaccine is not 
immediately available, the first injection should be given 
within 7 days of birth. The second and third doses should 
be given 1 to 2 months and 6 months, respectively, after the 
first. Testing for HBsAg and anti-HBs is recommended at 9 
to 18 months of age (3 to 12 months after the third dose) to 
monitor the success of therapy. If the mother’s HBsAg status 
is not known at the time of birth, the infant should be 
vaccinated within 12 hours of birth.
HBIG given at birth does not interfere with the administra-
tion of other vaccines administered at 2 months of age. 
Subsequent doses of hepatitis B vaccine do not interfere 
with the routine pediatric vaccine schedule.
Infants born to HBsAg-positive women and who weigh less 
than 2,000 grams at birth should receive postexposure 135
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prophylaxis as described above. However, the initial 
vaccine dose (at birth) should not be counted in the 3-dose 
schedule. The next dose in the series should be admin-
istered when the infant is chronologic age 1 month. The 
third dose should be given 1 to 2 months after the second, 
and the fourth dose should be given at 6 months of age. 
These infants should be tested for HBsAg and anti-HBs at 9 
to 18 months of age.
Women admitted for delivery whose HBsAg status is 
unknown should have blood drawn for testing. While test 
results are pending, the infant should receive the first 
dose of hepatitis B vaccine (without HBIG) within 12 hours 
of birth. If the mother is found to be HBsAg positive, the 
infant should receive HBIG as soon as possible but not 
later than 7 days of age. If the infant does not receive 
HBIG, it is important that the second dose of vaccine be 
administered at 1 or 2 months of age.
Preterm infants (less than 2,000 grams birthweight) whose 
mother’s HBsAg status is unknown should receive hepatitis 
B vaccine within 12 hours of birth. If the maternal HBsAg 
status cannot be determined within 12 hours of birth 
HBIG should also be administered because of the immune 
response is less reliable in preterm infants weighing less 
than 2,000 grams. As described above, the vaccine dose 
administered at birth should not be counted as part of 
the series, and the infant should receive three additional 
doses beginning at age 1 month.The vaccine series should 
be completed by 6 months of age.
Few data are available on the use of Comvax or Pediarix in 
infants born to women who have acute or chronic infec-
tion with hepatitis B virus (i.e., HBsAg-positive). Neither 
vaccine is licensed for infants whose mothers are known 
to be acutely or chronically infected with HBV. However, 
ACIP has approved off-label use of Comvax and Pediarix 
in children whose mothers are HBsAg positive, or whose 
HBsAg status is unknown. Comvax and Pediarix should 
never be used in infants younger than 6 weeks of age. 
Either vaccine may be administered at the same time as 
other childhood vaccines given at 6 weeks of age or older.
After a percutaneous (needle stick, laceration, bite) or 
permucosal exposure that contains or might contain HBV, 
blood should be obtained from the person who was the 
source of the exposure to determine their HBsAg status. 
Management of the exposed person depends on the HBsAg 
status of the source and the vaccination and anti-HBs 
response status of the exposed person. Recommended 
postexposure prophylaxis is described in the table on the 
next page.  9
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Non-Occupational Exposure to an HBsAg-
Positive Source
Persons who have written documentation of a complete 
hepatitis B vaccine series and who did not receive postvac-
cination testing should receive a single vaccine booster 
dose. Persons who are in the process of being vaccinated 
but who have not completed the vaccine series should 
receive the appropriate dose of HBIG and should complete 
the vaccine series. Unvaccinated persons should receive 
both HBIG and hepatitis B vaccine as soon as possible 
after exposure (preferably within 24 hours). Hepatitis B 
vaccine may be administered simultaneously with HBIG in 
a separate injection site.
Household, sex, and needle-sharing contacts of HBsAg-
positive persons should be identified. Unvaccinated sex 
partners and household and needle-sharing contacts should 
be tested for susceptibility to HBV infection and should 
receive the first dose of hepatitis B vaccine immediately after 
collection of blood for serologic testing. Susceptible persons 
should complete the vaccine series using an age-appropriate 
vaccine dose and schedule. Persons who are not fully vacci-
nated should complete the vaccine series. 137
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Non-Occupational Exposure to a Source with 
Unknown HBsAg Status
Persons with written documentation of a complete hepatitis 
B vaccine series require no further treatment. Persons who 
are not fully vaccinated should complete the vaccine series. 
Unvaccinated persons should receive the hepatitis B vaccine 
series with the first dose administered as soon as possible 
after exposure, preferably within 24 hours.
Contraindications and Precautions to 
Vaccination
A severe allergic reaction (anaphylaxis) to a vaccine 
component or following a prior dose of hepatitis B vaccine 
is a contraindication to further doses of vaccine. Such 
allergic reactions are rare.
Persons with moderate or severe acute illness should not 
be vaccinated until their condition improves. However, a 
minor illness, such as an upper respiratory infection, is not 
a contraindication to vaccination.
Specific studies of the safety of hepatitis B vaccine in 
pregnant women have not been performed. However, more 
than 20 years of experience with inadvertent administration 
to pregnant women have not identified vaccine safety issues 
for either the woman or the fetus. In contrast, if a pregnant 
woman acquires HBV infection, it may cause severe disease 
in the mother and chronic infection in the newborn baby. 
Therefore, hepatitis B vaccine may be administered to a 
pregnant woman who is otherwise eligible for it.
Hepatitis B vaccine does not contain live virus, so it may be 
used in persons with immunodeficiency. However, response 
to vaccination in such persons may be suboptimal.
Adverse Reactions Following 
Vaccination
The most common adverse reaction following hepatitis 
B vaccine is pain at the site of injection, reported in 
13%–29% of adults and 3%–9% of children. Mild systemic 
complaints, such as fatigue, headache, and irritability, have 
been reported in 11% to 17% of adults and 0% to 20% of 
children. Fever (up to 99.9°F [37.7°C]) has been reported in 
1% of adults and 0.4% to 6.4% of children. Serious systemic 
adverse reactions and allergic reactions are rarely reported 
following hepatitis B vaccine. There is no evidence that 
administration of hepatitis B vaccine at or shortly after birth 
increases the number of febrile episodes, sepsis evaluations, 
or allergic or neurologic events in the newborn period.
Hepatitis B vaccine has been alleged to cause or exacerbate 
multiple sclerosis (MS). A 2004 retrospective study in a   9
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British population found a slight increase in risk of MS 
among hepatitis B vaccine recipients. However, large popu-
lation-based studies have shown no association between 
receipt of hepatitis B vaccine and either the development of 
MS or exacerbation of the course of MS is persons already 
diagnosed with the disease.
Vaccine Storage and Handling
Hepatitis B vaccines should be stored refrigerated at 
35°–46°F (2°–8°C), but not frozen. Exposure to freezing 
temperature destroys the potency of the vaccine.
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